Vaccine Immunotherapy for Prostate Cancer
Annual rept. 15 Apr 2008-14 Apr 2009
IOWA UNIV IOWA CITY
Pagination or Media Count:
The purpose of the research supported by this award is to conduct a Phase II clinical trial study of an adenovirusPSA AdPSA vaccine for the treatment of prostate cancer. Two protocols have been used in the trial 1 - Phase II study of AdenovirusPSA vaccine in men with recurrent prostate cancer after local therapy and 2 - Phase II study of AdenovirusPSA vaccine in men with hormone refractory prostate cancer. In the first protocol men with newly recurrent prostate cancer were randomized to one of two arms of the study. Patients in Arm A received the AdPSA vaccine only three injections spaced 30 days apart. Patients in Arm B received androgen deprivation therapy ADT followed at day 14 by the AdPSA vaccine, again with three injections. In the second protocol men with hormone refractory prostate cancer were injected with the vaccine only, three injections 30 days apart. The patients were followed for toxicity, the development of anti-PSA immune responses, and evidence of a clinical effect of the vaccination. The latter includes changes in serum PSA and prostatic acid phosphatase PAP levels and in the PSA doubling times PSADT. Patients in protocol 2 also have CT and bone scans to monitor their prostate cancer.
- Medicine and Medical Research